clinical trial · NCT05134922
Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009
Breast Neoplasm Malignant FemaleGedatolisib
brief summary
Continued access to treatment for subjects who continue benefit from therapy with gedatolisib in combination with palbociclib, and fulvestrant or letrozole.
started
—
primary completion
—
completion
—
last updated
Mar 21, 2025
detailed description
The primary purpose of this study is to provide continuing access to treatment for subjects who continue benefit from therapy with gedatolisib in combination with palbociclib, and fulvestrant or letrozole.
official title
Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in a Celcuity-Sponsored Clinical Study (B2151009)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol